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SUMMARY AND CONCLUSIONS
The  s tud ies  desc r i bed  i n  t h i s  t hes i s  we re  i n i t i a ted  w i th  t h ree  ma in  a ims :
F i r s t ,  t o  deve lop  a  p rac t i ca l  and  sens i t i ve  me thod  fo r  se rod iagnos i s  o f
human  cy tomega l  ov i rus  (  CMV) - i n fec t i ons  and  to  de te rm ine  the  re l  a t i ve  d iag -
nos t i c  va lue  o f  I gM and  IgG an t i body  responses  to  d i s t i nc t  CMV-an t i gens .
Second,  to test  the hypothesis  that  ant ibody responses d i rected against  the
CMV-MA comp lex  I oca ted  on  the  ou te r  su r face  o f  CMV- in fec ted  ce l I s  wou ld
con t r i bu te  t o  t he  recove ry  f r om in fec t i on ,  espec ia l l y  i n  pa t i en t s  rece i v i ng
immune  supp ress i ve  t he rapy  and ,  i n  add i t i on ,  t o  s tudy  the  re la t i on  o f  t he
CMV-MA comp lex  t o  o the r  CMV-an t i gens .
Th i rd ,  t o  de te rm ine  the  mo lecu la r  na tu re  o f  CMV-an t i gens  tha t  a re  recogn i zed
by  human  se rum an t i bod ies  du r i ng  acu te  and  l a ten t  CMV- in fec t i on .
Fo r  t hese  s tud ies  se ra  we re  co l l ec ted  l ong i t ud ina l l y  ove r  a  pe r i od  o f  5
yea rs  f r om ind i v i dua l  s  w i t h  a  d i f f e ren t  immune  s ta tus  backg round ,  hav ing
e i t he r  a  l a ten t  o r  ac t i ve  CMV- in fec t i on .  The  pa t i en t s  we re  immunecompromised
rena l  a l l og ra f t  r ec ip ien ts  w i t h  a  p r imary  o r  seconda ry  CMV- in fec t i on  and
non -compromised  pa t i en t s  w i t h  commun j t y -acqu i red  o r  pos t - t r ans fus ion  CMV-
in fec t i ons .  The  con t ro l s  we re  rena l  a l l og ra f t  r ec ip ien ts  t ha t  rema ined  w i th -
ou t  CMV- in fec t i on  and  hea l t hy  l abo ra to ry  and  hosp i t a l  pe rsonne l .
Previous studies f rom our  laborator-y had shown that  the bulk of  CMV-ant ibo-
d ies  f o rmed  i n  response  to  CMV- in fec t i on  was  d i rec ted  aga ins t  CMV-an t i gens
o f  t he  ea r l y  (CMV-EA)  and  l a te  (CMV-LA)  an t i gen  comp lex ,  ma in l y  l oca ted  i n
the  nuc leus  o f  t he  i n fec ted  ce l l .
Based  upon  these  obse rva t i ons  an  enzyme- l i nked  immunoso rben t  assay  (EL ISA)
was developed for  the detect ion of  IgM and IgG ant ibodies to CMV-EA and CMV-
LA  sepa ra te l y ,  as  desc r i bed  i n  chap te r  2 .  I nc reas jng  the  ra t i o  o f  CMV-an t i -
gen i c  p ro te ins  re la t i ve  t o  t he  t o ta l  p ro te in  con ten t  i n  who le  ce l I  ex t rac t s ,
used  as  an t i gen  fo r  t he  EL ISA- tes t ,  g rea t l y  improved  the  sens i t Í v i t y  o f  t he
techn ique .  A  de ta i l ed  p rocedu re  fo r  op t ima l  and  rep roduc Íb le  p roduc t i on  o f
the i  ndi  v i  dual  CMV-ant i  gens i  s  i  nc l  uded.
In  t h i s  and  a l l  subsequen t  s tud ies  i t  was  found  tha t  CMV-an t i gens  p repa red
f rom CMV-s t ra in  AD169  a l l owed  the  spec i f i c  de tec t i on  o f  an t i bod ies  t o  human
CMV and  d id  no t  c ross - reac t  w i t h  an t i gens  f rom o the r  human  he rpesv i ruses .
The  i n f l uence  o f  I gM- rheumato id  f ac to r  wh i ch  may  g i ve  a  f a l se  pos i t i ve  CMV-
IgM reac t i on  was  m in jma l i zed .  Howeve r ,  i t  was  essen t i a l  t o  t es t  a l l  se ra  f o r
reac t i on  w i th  con t ro l  an t i gen  f rom non - i n fec ted  ce l l s  i n  o rde r  t o  exc lude
poss ib le  f a l se  pos i t i ve  reac t i ons  due  to  t he  p resence  o f  "au to -an t i bod Íes " .
The  EL lSA-me thod  i s  shown  to  be  o f  equa l  o r  s l j gh t l y  h ighe r  sens Í t i v i t y  i n
detect ing CMV-ant ibodies compared to the indi rect  immunof luorescence t s t
and  s ign i f i can t l y  more  sens i t Í ve  compared  to  t he  comp lemen t - f i xa t i on  t ech -
n ique .  The  p resence  o f  even  l ow  l eve l s  o f  na tu ra l l y  acqu i red  c j r cu la t ' i ng
CMV-ant ibodies ref lects prev ' ious exposure to CMV and therefore possib le
latent  v i rus carr iership which may not  be detected w' Í th  other  sero logical
techniques.  Thus,  the ELlSA-method is recommended for  the select ion of  CMV-
se ronega t i ve  (b lood )  dono rs .  Th i s  t ype  o f  dono r - se lec t i on  i s  spec ia l l y  i nd i -
cated to prevent  CMV-transmiss ion to pat ients at  r isk of  developing a
pr imary CMV-i  nfect ion.
The  rep roduc ib i l i t y  o f  t he  me thod ,  i nc lud ing  the  an t i gen  p repa ra t i on ,  f ac i -
l i ta tes longi tudinal  s tudies and abrogates the need of  retest ing previous
serun samples.  The appl icat ion of  the CMV-ELISA test  for  rout ine CMV-
se ro logy  i s  i nc luded  i n  chap te r  6 .
Heal thy donors and longtFmff i ïvors af ter  renal  t ransplantat ion showed a
s tab le  CMV-se ro logy  ( l ess  t han  4 - fo ld  f l uc tua t i ons  o f  an t i body  t i t e r s  i n
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Isubsequen t  se ra )  ove r  
. a^2 :1  yea r -  pe r i od .  consequen t l y ,  changes  i n  an t i bodyt i t e r s  exceed ing  the  4 - fo ld  l eve l  a re  cons ide red  to  bè  o t  d j agnos t i c  va lué
and  may  i nd i ca te  ongo ing  CMV- in fec t i on  i n  t he  pa t i en t  w i t h  concómi tan t  exoo -
su re  o f  v i r a l  an t i gens  to  t he  immune  sys tem.
Despi te the Iack of  detectable lymphocyte-react iv i ty  in  renal  a1 Iograf t
r ec ip ien ts  ( t hese  da ta  w i l l  be  sub jec t  o f  t he  f o r thèominq  thes i s  o f  H . t { .
Roenho rs t )  an t i bod ies  t o  cMV-an t i gens  appea r  i n  t he  c i r èu la t i on  o f  mos tpa t i en t s  a t  o r  sho r t l y  a f t e r  onse t  o f  c l i n i ca l  symp toms  o f  cMV- ín fec t i on .
Their  detect ion may be of  help for  the d iagnosis and the choice of  therapy
' i  n  these oat i  ents.
I n  t h i s  respec t ,  an t i bod ies  o f  t he  I gM-and  IgG-c1ass  d i rec ted  aga ins t  t heCMV-LA  comp lex  we re  o f  d i agnos t i c  va lue  and  were  the  ea r l i es t  án t i bod ies
de tec tab le  i n  resp_o_nse  to  cMV- in fec t i on .  I gG  an t i  cMV-LA  showed  a  s i gn i f i -
can t  i nc rease  i n  a l l  pa t i en t s  and  IgM an t i  cMV-LA  was  de tec tab le  ( f r eq ien t l y
be fo re  I gG)  Í n  a l l  cases  o f  p r Ímary  cMV- in fec t i ons  and  i n  7 l% o f  t he  secon -da ry  cMV in fec t i ons .  The  t i t e r  o f  CMV-LA  IgM was  pos i t Í ve l y  re la ted  to  v i r us -
exc re t i on  i n  u r i ne  o r  sa l i va  i n  t hese  pa t i en t s .
In th is  s tudy the ant ib ,ody responses to CMV-EA were not  found to prov ide
add i t i ona l  i n fo rma t i on ,  f o r  t he  se rod iagnos i s .  I n  compar i son  to  comp iemen t -
f i xa t i on  se ro logy  the  CMV-EL ISA  tes t  may  a l l ow  more  ráp id  i den t i f i cà t i on  o f
CMV- in fec t i on  Í n  rena l  a l l og ra f t  r ec ip ien ts .  Th i s  shou ld  be  fu r the r  t es ted
i  n  p rospec t i  ve  s tud i  es  .
In terest ingly ,  despi te the immune suppressive therapy the group of  renal
a l l og ra f - t  r ec Íp ien ts  had  s ign i f i can t  h ighe r  an t i body  t i t e r s  compáred  to  t hepreviously .  heal  thy,  non- immune compromi ied pat ient i  wi th act ive '  symptomat ic
cMV- in fec t i ons .  Th i s  may  re f l ec t  a  h ighe r  exposu re  t o  cMV-an t i gdns  i n  t heformer pat ients and adds to the possib le d iagnost Íc  value of  ar i t ibody res-ponses  i n  t h_ese  pa t i en t s .0n  the  o the r  hand  the  i nc reased  an t i body  re iponse
may  be  o f  va lue  fo r  pa t i en t ' s  recove ry  espec ia l l y  s i nce  ce l l -med ia ied  Ímmune
mechan isms  may  be  re la t i ve l y  i ne f f i c i en t  j n  immune  supp ressed  pa t i en t s .  Th i s
was  the  sub jec t  o f  t he  second  pa r t  o f  t he  i nves t i ga t i ons .
cons ide r i ng . ! he  ce l  l - assoc ia ted  na tu re  o f  human  cMV i t  was  hypo thes i zed  tha t
ant ibody-mediated recogni t ion and destruct ion of  CMV-infec ied cel  I  s  would
l imi t .  v i ra l  spread and thus contr ibute to the host 's  recovery.  In  order  to
corroborate th- is  hypothesis  we moni tored the development  of  tgM and IgG and
cy to l y t i c  an t Íbod ies  t o  CMV-MA in re la t i on  t o  t he  c l i n i ca l  cou rse  o f  ác t i ve
and latent  cMV-infect ions in  pat ients wi th a d i f ferent  immune status back-g roun0 .
For the speci f ic  detect ion of  IgM and IgG ant ibodies to cMv-MA i t  proved to
be  essen t i a l  t o  mod i f y  p rev ious l y  pub l i shed  me thods  as  desc r i bed  i n  chap te r
!-. A micropl ate mod j f ication of the improved membrane immunofl uor6ffiG
method  tha t  f ac i  l  i t a ted  the  s imu ] taneous  ana l ys i s  o f  mu l t i p l e  samp les  i s
a l so  desc r Íbed .  The  use  o f  v i ab le  cMV- in fec ted  ce l l s ,  kep t  a t  0 -4 ' c  was
requ i red  Ín  o rde r  t o  m Ín ima l i ze  poss ib le  reac t i ons  w i th  i n t race l  I u l a r  CMV-
ant igens and the cMV-induced Fc-receptor .  The speci f ic i ty  of  the cMv-MA
react ion was conf i rmed by us ing monoclonal  ant ibodies d i rected against
i n t race l l u l a r  cMV-an t i gens .  No  re la t i on  was  found  be tween  an t i body  i Í t e r s
aga ins t  cMV-MA and  those  aga ins t  i n t race l l u l a r  cMV-an t i gens  i n  human  se ra
suggest ing that  d i f ferent  ant igens were bound.  This is  fur ther  extended in
chao te r  4  and  5 .
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desc r i bed  i n  chap te r  4 .
A fi rst set IF-TX|V--MA mol ecu les was found to appear on the surf ace of
i n fec ted  ce l l s  as  ea r l y  as  6 -12  hou rs  a f t e r  v i r us - i nocu la t i on  and  i n  t he
absence of  v i ra l  DNA-synthesis  remained detectable for  120 hours (CMV-EMA).
Another  set  of  CMV-MA molecules appeared,  at  about  36-48 hours af ter  Ín fec-
t ion (CMV-LMA) af ter  onset  of  v i ra l  DNA-synthesis .  These ant igens were
discr imjnated f rom CMV-EMA by a d i f ferent  d is t r ibut ion over  the membrane,  a
d i f f e ren t  reac t i on  w i th  some  human  se ra ,  t he i r  sens i t i v i t y  t o  j nh ib i t i on  o f
v i ra l  DNA-polymerase act iv i ty  and by absorpt ion exper iments.
The appearance of  CMV-MA molecules as detected in  these studies proved to be
cons ide rab l y  ea r l i e r  i n  t he  i n fec t i on -cyc le  o f  CMV than  desc r i bed  thus fa r .
Howeve r ,  t he i r  i n i t i a l  dens i t y -d i s t r i bu t i on  i s  ve ry  1ow.  l , { e  f ound  tha t  an t i -
bodies to CMV-EMA were not  a lways present  in  sera contaÍn ing CMV-LMA ant ibo-
d ies whereas the same sera conta ined eoual  levels  of  ant ibodies to in t ra-
ce t l u l a r  an t i gens  o f  t he  CMV-EA comp lex .  The  reason  fo r  t h i s  appa ren t  d i f -
f e rence  i s  no t  known  a t .D resen t .
The capaci ty  of  CMV-MA ant ibodies to mediate the destruct Íon of  CMV-infected
qg11s was determined in a complement-dependent  cy oly t ic  assay based upon
" 'Ch rom ium- re lease  as  desc r i bed  i n  chap te r  5 .
Due  to  t he  l ow  dens i t y -d i s t r i bu t i on  o f  CMV-EMA mo lecu les  no  e f f ec t i ve  l ys i s
o f  CMV- in fec ted  ce l l s  was  ob ta ined  w i th  human  se ra  ea r l y  i n  t he  i n fec t i ous
cyc1e .  Concu r ren t  w i t h  t he  appea rance  o f  CMV-LMA mo lecu les  CMV- Ín fec ted
cel ls  were more ef f ic ient ly  lysed and the amount  of  lys is  was re lated to the
an t i body  t i t e r  aga ins t  CMV-MA in  t he  se rum used .
CMV-cyto ly t ic  ant ibodies were never  observed in heal  thy CMV-seroposi t ive
contro ls  and were only detectable in  pat ients wÍ th a recent  CMV-infect ion.
The  h ighes t  l eve l s  o f  CMV-cy to l y t i c  an t i bod ies  we re  found  j n  rena l  a l l og ra f t
r ec ip ien ts  w i t h  a  seconda ry  CMV- in fec t i on .  By  i so la t i ng  t he  IgG f rac t i on
from the sera of  these pat ients,  we could demonstrate that  the lys is  of  CMV-
in fec ted  ce l l s  i s  a l so  med ia ted  by  human  IgG-an t i bod ies ,  t he reby  ex tend ing
previous observat Íons by others.
An interest ing f ind ing in  th is  s tudy was the observat ion that  pur i f ied CMV-
vi r ions were rather  inef f ic ient  in  absorbing CMV-cyto ' ly t ic  ant ibody act Í -
v i t y ,  whe reas  non -pu r i f i ed  v i r i on -p repa ra t i ons ,  s t i ' l  I  con ta Ín ing  ce1  1 -mem-
brane f ragments,  were near ly  as ef f ic ient  as jn tact  CMV-infected cel  l  s .
These data suggest  that  the ant igenic make-up of  the v i r ion envelope and the
p1asma membrane of  the in fected cel  I  are ( in  par t )  d i f ferent  f rom each
other .  These f ind ings are supported by addi t Íonal  data as ment ioned in
chapter  5.  However,  as to date the precise molecu' lar  nature of  the CMV-MA
complex remains to be determined (see a lso chapter  7) .
Using the above ment ioned techniques -  ELISA, membrane immunof luorescence
and cyto ly t ic  ant ibody assay -  we moni tored the development  of  ant ibody
responses to the d is t inct  CMV-ant igens,  CMV-EA, CMV-LA, and CMV-MA, in  re la-
t ion to c l in ica ' l  and v i ro logical  parameters as shown in chapter  6.  The
diagnostical aspects of anti6ody rdsponses to the intracelfiTáïTFiV:anti-
gens,  CMV-EA, and CMV-LA have been sumnar ized above.
ïhe neasurement  of  ant ibody responses to CMV-MA did not  have d iagnost ica l
va1ue s ince they d id not  develop in  a l l  pat Íents.  Therefore the CMV-ELISA
technique is  preferred for  d iagnost ica l  purposes.  However,  besides being of
d iagnost ica l  va lue CMV-ant ibodies contr ibute to the host 's  recovery.  In
par t icu lar ,  the development  of  ant ibody responses to CMV-MA may be of
prognost ica l  va lue s ince thei r  occurrence appeared to be re lated to sub-
sequent recovery from CMV-dísease.
In th is  s tudy no cyto ly t ic  ant ibodies were found in the few cases of  fa ta l
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CMV- in fec t i on .0n  the  o the r  hand  the  p resence  o f  s i gn i f i can t  l eve l s  o f  an t i -
CMV-MA an t i bod ies ,  pa r t i cu la r l y  t he  cy to l y t i c  ones ,  re la ted  w i th  t he  sub -
sequent  recovery f rom infect ion.  Such a re lat ion was not  found for  ant ibody
responses  to  i n t race l l u l a r  CMV-an t i gens  as  measu red  by  EL ISA .
The development  and level  of  CMV-MA and cyto ly t ic  ant ibody responses was
posi t ive ly  re lated to both shor t - term and long- term recovery f rom CMV-
in fec t i on .  Fo r  k i dney  t ransp lan t  pa t i en t s  w i t h  a  seconda ry  CMV- in fec t i on  -
who  deve l  oped  the  h ighes t  an t i body  responses  to  CMV-MA -  a  s i gn í f i can t
re lat ion was found between the level  of  the cyto ly t ic  ant ibody response and
the  g ra f t - f unc t i on  a t  one  yea r  f o11ow-up ,  be ing  be t te r  i n  pa t i en t s  t ha t  had
the  h ighes t  cy to l y t i c  an t íbody  responses .
Th i s  re la t i onsh ip  was  no t  as  c l ea r l y  f ound  fo r  a l l og ra f t  r ec ip ien ts  w i t h  a
p r imary  CMV- in fec t i on  wh i ch  may  be  re la ted  to  a  l ess  e f f i c i en t  r esponse  due
to the lack of  pre-exis t ing CMV-MA memory lymphocytes.  In  addi t ion,  the
re lat ive low level  of  CMV-MA ant ibody responses in non- jmmunocompromised
pa t i en t s  w j t h  a  CMV- in fec t i on  sugges ts  t ha t  recove ry  f r om in fec t i on  i n  t hese
pa t i en t s  may  be  success fu l l y  med ia ted  by  ce l  l u l a r  p rocesses .  Howeve r ,  a l so
in these pat ients the development  of  a h igh cyto ly t ic  ant ibody response was
parale l led by a more rapid recovery and by the absence of  re lapse of  symp-
toms.
A  poss ib le  exp lana t i on  f o r  t he  obse rved  h Ígh  f requency  o f  CMV- in fec t i ons  i n
rena l  a1  l og ra f t  r ec ip ien ts ,  espec ia l  1y  conce rn ing  the  seconda ry  i n fec t Í ons
due  to  reac t i va t i on  o f  endogenous  CMV,  i s  desc r i bed  i n  t he  d j scuss ion  sec -
t i on  o f  chap te r  6 .
Our resu-1Tí to!'eTher with recent data from other groups indicate an impor-
tant  ro le for  immunological  recogni t ion of  CMV-MA in the recovery f rom
CMV-infect ion.  I t  is  therefore suggested that  improvement  of  the host 's
immuni ty  to these CMV-ant igens may s igni f icant ly  contr ibute to prevent  and
l im i t  symp toma t i c  CMV- in fec t i ons  i n  t he  human  hos t .  Th i s  may  be  ach ieved  by
ac t i ve  immun iza t i on  t h rough  vacc ina t i on  w i th  CMV-MA con ta in ing  ( subun i t )
vacc ins ,  o r  by  pass i ve  Ímmun iza t i on  us ing  hype r immune  human  se ra  con ta in ing
CMV-MA cy to l y t i c  an t i bod ies .  These  se ra  have  to  be  ob ta ined  f rom ind i v i dua l s
recover ing f rom a recent  CMV-infect ion s ince the sera f rom heal thy la tent ly
infected donors lack the ef fect ive ant ibodies.  The methods reoui red for  th is
se ro log i ca l  se lec t i on  a re  ou t l i ned  i n  t he  chap te rs  3  and  5 .
In chapter  7 a star t  was made to character ize the molecular  nature of  CMV-
ant fuei í recognized by human serum ant ibodies.  I t  was found that  the ant i -
body responses of  ind iv Íd i ra l  s  wi th e i ther  a la tent  or  an act ive and
symptomat ic  CMV-infect ion predomÍnant ly  were d i rected against  ant igens pre-
sent  in  the nuc ' leocapsid f ract ion of  CMV-infected ce ' l ls .  These CMV-ant igens
had molecular  weights s imi lar  to  the st ructura l  component  of  the v i r ion,
suggest ing possib le ident i ty .  These observat ions are in  agreement  wi th the
serological  data which show that  hunan serum ant ibodies are predominant ly
d i rec ted  aga ins t  an t i gens  o f  t he  CMV-LA  comp lex ,  wh i ch  a re  ma in l y  l oca ted  i n
the  nuc lea r  i nc lus ions  o f  CMV- in fec ted  ce l  I s  be ing  the  s i t es  o f  v i r i on
assemb ly .
An important  observat ion in  th is  s tudy was the apparent ly  o l igoclonal  ant i -
body response in pat ients at  r isk of  developing a symptomat ic  CMV-infect ion
af ter  renal  t ransplantat ion and immunosuppression.  This was even f l tore pro-
nounced in those pat ients that  had the most  severe c ' l in ica l  course and may
be one of  the factors that  determine the outcome of  CMV-infect ion,  e i ther  as
subc l i n i ca l  i n fec t i on  o r  symp toma t i c  d i sease .  These  o l  i goc lona l  r esponses
are not  ref lected by the sero logical  data which measure "overal  | "  ant ibody
responses to a comp' lex of  CMV-ant igens of  which some components are c lear ly
immunodorninant  by v i r tue of  thei r  abundancy.
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Fur ther  s tudies are c lear ly  needed in th is  f ie1d,  in  par t icu lar  for  the e ' lu-
c idat ion of  the molecular  composi t ion of  the CMV-MA complex.  The development
of  monoclonal  ant ibodies wi th def ined speci f ic i ty  for  CMV-MA mo' lecules may
be of  great  help in  th is  and may e luc idate in  more deta i l  the ro ' le  of  ind i -
v idual  CMV-MA components in  host 's  innunologica ' l  defence wtr ich ís  a major
determinant  for  recovery f rom infect ion and maintenance of  l i fe- long CMV-
1 atency.
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